Login or sign up
For business

Topica pharmaceuticals

4.3· 7 reviews
Average ratingGreat
4.3/ 5

Based on 7 reviews

543%
443%
314%
20%
10%
Ask AI

Ask AI about Topica pharmaceuticals

Generated with AI from 7 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Chelsie Kramer
Reviews 1

I recently made a purchase from an online pharmacy and I am extremely satisfied with the products. They provided effective medications and the results were amazing. The website was user-friendly and the overall experience was pleasant. I would definitely recommend this company.

Ed Perry
Reviews 1

I recently purchased some medications from a website, and I must say, I am impressed with the quality. The products worked effectively and I am satisfied with the results. The customer service was also great, they provided timely support. Overall, I had a positive experience with Topica Pharmaceuticals.

Ashvini Rao
Reviews 1

I have been using products from Topica Pharmaceuticals for a while now and I must say, they are excellent. The quality of their medications is top-notch and I have never had any issues with their products. The website is also very user-friendly and easy to navigate. I highly recommend them!

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Topica pharmaceuticals

TOPICA Pharmaceuticals, Inc. is a privately held clinical research stage pharmaceutical company focused on developing luliconazole for the treatment of onychomycosis, fungal infections of the nail. More than 35 million Americans are estimated to suffer from onychomycosis for which treatment
options are limited. In addition to luliconazole’s highly potent anti-fungal activity and excellent safety profile, the molecule is able to rapidly cross the nail plate reaching the site of the infection in the nail bed. In a Phase 1/2a clinical trial completed in 2011, TOPICA demonstrated the ability of its
3 proprietary 10 percent luliconazole solution to rapidly cross the nail plate and was well tolerated by patients. The company is now focused on conducting a robust dose finding and proof of efficacy study with luliconazole in onychomycosis starting in mid 2012 with the goal of making luliconazole the first highly effective and safe topical therapy for the treatment of onychomycosis.

Categories
Pharmaceuticals